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DNAzyme (Dz) molecules have been shown to be highly efficient inhibitors of virus replication.
Hepatitis C virus RNA translation is mediated by an internal ribosome entry site (IRES) element
located mostly in the 59 untranslated region (UTR), the mechanism of which is fundamentally
different from cap-dependent translation of cellular mRNAs, and thus an attractive target for
designing antiviral drugs. Inhibition of HCV IRES-mediated translation has drastic consequences
for the replication of viral RNA as well. We have designed several Dzs, targeting different regions
of HCV IRES specific for 1b and also sequences conserved across genotypes. The RNA
cleavage and translation inhibitory activities of these molecules were tested in a cell-free system
and in cell culture using transient transfections. The majority of Dzs efficiently inhibited HCV
IRES-mediated translation. However, these Dz molecules did not show significant inhibition of
coxsackievirus B3 IRES-mediated translation or cap-dependent translation of reporter gene,
showing high level of specificity towards target RNA. Also, Northern blot hybridization analysis
showed significant cleavage of HCV IRES by the Dz molecules in Huh7 cells transiently
transfected with the HCV–FLuc monocistronic construct. Interestingly, one of the Dzs was more
effective against genotype1b, whereas the other showed significant inhibition of viral RNA
replication in Huh7 cells harbouring a HCV 2a monocistronic replicon. As expected, mutant-Dz
failed to cleave RNA and inhibit HCV RNA translation, showing the specificity of inhibition. Taken
together, these findings suggest that the Dz molecule can be used as selective and effective
inhibitor of HCV RNA replication, which can be explored further for development of a potent
therapeutic agent against HCV infection.
INTRODUCTION
Hepatitis C virus (HCV) is a single-stranded positive-sense
RNA virus, belonging to the family Flaviviridae. The viral
RNA genome is approximately 9600 nt and encodes a
single polyprotein of about 3000 amino acids. The long
open reading frame is flanked by 59 and 39 untranslated
regions (UTRs) that are highly conserved among the
majority of HCV genotypes and contain elements that are
essential for genome replication (Bartenschlager et al.,
2004). The translation initiation of HCV RNA is mediated
by the binding of the 40S ribosomal subunit at the internal
ribosome entry site (IRES) located mostly in the 59UTR
region. It has been shown that the HCV IRES can directly
bind to the 40S ribosomal subunit, even in the absence of
any initiation factors, in a manner similar to prokaryotic
translation initiation. Subsequently, several canonical and
non-canonical trans-acting factors facilitate the formation
of a functional initiation complex during internal initiation
of translation (Hellen & Sarnow, 2001). Since this
mechanism is fundamentally different from the ribosome
assembly at the 59 cap-binding complex in cap-dependent
translation of host cell mRNA, it serves as an attractive
target for antiviral agents (Dasgupta et al., 2004).
HCV causes a multitude of liver diseases in humans,
including liver cirrhosis, and often leads to hepatocellular
carcinoma if left untreated. Current treatment options
involving interferon-a (INF-a) alone or in combination
with ribavirin are not very effective. The majority of the
patients do not respond well to this therapy because of
the short half-life of interferon or degradation of the
molecules. Failure to achieve a sustained virological
response in majority of the patients has also been shown
to be partly due to the varying genotypes of the infecting
strain of the virus. HCV has six major genotypes with
several subtypes. HCV genotype 1 has been shown to be
more resistant to interferon therapy than genotype 3.
Genotype 3 was found to be the most prevalent in India,
followed by genotype 1 (Gupta et al., 2006). Thus
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developing effective antiviral therapeutics using novel
approaches is the need of the hour.
Several strategies are being explored to develop antiviral
agents against HCV, targeting different viral processes.
Recent availability of HCV subgenomic (Lohmann et al.,
1999) and full-length (Blight et al., 2002) replicon systems
has helped immensely to assay the inhibitory effect of
antiviral candidates on HCV genome replication. Earlier,
several studies have shown effective inhibition of viral RNA
translation when viral enzymes were targeted. Since the
translation of genomic RNA is the initial obligatory step,
interference with this process will have direct consequence on
the viral RNA replication. HCV RNA is translated by
recruitment of the ribosome at the IRES element which
comprises most of the 59UTR sequences (except the first
40 nt) and extends to a short stretch of 30–40 nt downstream
of the initiator AUG. Since the IRES-mediated translation is
distinct from the cap-dependent translation of host cell
mRNA, this could be exploited by different approaches to
achieve selective inhibition of HCV gene expression.
Currently, nucleic-acid-based antiviral approaches, which
include ribozyme (Rz), DNAzyme (Dz), short hairpin RNA
(shRNA) and small interfering RNA (siRNA), are being
used for inhibiting the gene expression of several target
RNAs (Jarczak et al., 2005; Goila & Banerjea, 2004).
Among these, catalytic Dzs with 10–23 catalytic motifs are
increasingly being exploited over Rzs because they either
match or exceed the catalytic efficiencies of the known Rzs.
Deoxyribozymes or DNAzymes or DNA-enzymes (Dzs), as
originally described (Santoro & Joyce, 1997), are short
DNA molecules that can be designed to cleave any target
RNA in a sequence-specific and catalytic manner
(Silverman, 2005, Dash & Banerjea 2004; Joyce, 2004).
Dzs are synthetic single-stranded DNA molecules which
have three domains: a catalytic domain consisting of 15 nt
flanked by two substrate-recognition domains which bind
the target RNA through Watson–Crick base pairing. In Dzs
a single nucleotide change in the 10–23 catalytic motif
completely abrogates the sequence-specific cleavage activ-
ity; for example, G14C completely abolishes the catalytic
cleavage (Goila & Banerjea, 2001). In some instances
efficient inhibition of gene expression was achieved with
10–23 Dz (Ackermann et al., 2005). Based on sequence
recognition of the binding arms, Dzs can be synthesized to
cleave a target gene in a sequence-specific manner similar
to that of Rzs (Asahina et al., 1998; Goila & Banerjea,
1998).
Compared with synthetic Rzs, Dzs are easier to prepare, less
sensitive to chemical and enzymic degradation and, more
importantly, easier to deliver into cells (Santoro & Joyce,
1997). Over the years, several kinds of Dzs with unique
catalytic motifs have been described, but Dzs possessing the
10–23 catalytic motif have been exploited more extensively
by several investigators (Banerjea et al., 2004). Various
studies suggest that all the target sites are not available for
cleavage by a single kind of catalytic nucleic acid molecule,
most probably because the secondary and tertiary structures
in the target RNA prevent optimal Watson–Crick base
pairing with Rzs or Dzs. More than one site is usually
selected in the target RNA to get maximum cleavage by
catalytic nucleic acids. 10–23 DNA-enzyme cleaves the RNA
sequence at a phosphodiester bond between an unpaired
purine and a paired pyrimidine residue (59-AU-39 most
efficiently cleaved). This results in the formation of 59 and 39
products, which contain a 29-39cyclic phosphate and 59
hydroxyl terminus, respectively (Santoro & Joyce, 1998).
METHODS
Deoxyribozyme synthesis. All the oligodeoxynucleotides (ODNs)
were synthesized chemically and obtained from Sigma Genosys. The
conserved 15 nt (59-GGCTAGCTACAACGA-39) 10–23 catalytic
motif was flanked on both sides by substrate-binding arms of the
Dz that were made complementary to the target RNA. Mutant-Dz was
also assembled using a 10–23 catalytic motif that possessed a single
nucleotide substitution (G to C) in the 10–23 catalytic motif. This
change is known to render the Dz catalytically inactive (Goila &
Banerjea, 2001).
We have initially designed five DNA-enzymes, namely Dz88, Dz219,
Dz305, Dz327 and Dz336, targeting different regions of HCV 59UTR
IRES (Table 1). Additionally, mutant-Dz219, possessing a point
mutation as stated above, was designed, which is termed the ‘mutant
Dz’. These molecules were specific only for HCV genotype 1b. Later
we designed another four 10–23 catalytic motif-containing Dzs,
namely Dz161, Dz165, Dz285 and Dz288, that were targeted to cleave
59UTR regions of all the currently known HCV genotypes (Table 2).
The location of cleavage for each Dz is shown by arrows in the
predicted 59-UTR IRES (Fig. 1).
Cell culture and plasmid. Human hepatocellular carcinoma cells
(Huh-7 and Huh-7.5 cells) monolayers (Blight et al., 2002) were
maintained in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% heat-inactivated fetal bovine serum (FBS)
at 37 uC in 5% CO2 atmosphere. For cells supporting the HCV full-
length replicon (genotype 1b), 0.8 mg G418 sulfate ml21 (Sigma-
Aldrich) was added to the culture medium and for cells bearing the
HCV monocistronic replicon (genotype 2a), 25 mg hygromycin B
ml21 was added to the culture medium. Replicon 1b carries the 1b
genotype HCV 59UTR followed by a neomycin resistance gene (neo),
EMCV IRES and NS2–NS5 and the 39UTR sequence. The replicon 2a
carries the 2a genotype HCV 59UTR followed by a hygromycin
resistance gene (hyg), a ubiquitin gene (ubi) and NS3–NS5 and the
39UTR. The HCV–FLuc monocistronic plasmid construct pCD
(HCV–IRES–FLuc) construct carrying HCV IRES (nt 18–383) was
Table 1. Sequence of DNAzymes for subtype 1b
The mutated residue in the mutant mutDz-219 is highlighted in bold.
DNAzyme Sequence 5§–3§
Dz88 AACGCCAGGCTAGCTACAACGAGGCTAGAC
Dz305 GCAAGCAGGCTAGCTACAACGACCTATCAG
Dz219 CCAGGCAGGCTAGCTACAACGATGAGCGG
Dz327 CTACGAGAGGCTAGCTACAACGACTCCCGG
Dz336 TGCACGGGGCTAGCTACAACGACTACGAG
mutDz219 CCAGGCAGGCTAGCTACAACCATGAGCGG
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cloned upstream of the gene for the firefly luciferase (Pudi et al.,
2003). The pCDFLuc construct contains the luciferase reporter gene
and the coxsackievirus B3 (CVB3)–FLuc monocistronic plasmid
construct (pCDCVB3-IRES-FLuc) contains the CVB3 59UTR cloned
upstream of the firefly luciferase reporter gene.
In vitro cleavage of target RNA with Dz. In vitro run off transcripts
of HCV IRES RNA (387 nt) was made from linearized HCV–FLuc
monocistronic construct DNA (containing nt 18–383 of HCV IRES)
using the T7 RNA polymerase (Promega) in the presence of
[a-32P]UTP, following the manufacturer’s protocol. The extra
nucleotides in the labelled transcript (387 nt) came from the region
between the T7 promoter and upstream of the HCV sequence (cloned
in polylinker). Equimolar amounts of unlabelled Dz and labelled
substrate RNA (100 pmol each) were allowed to interact in a final
volume of 10 ml in a buffer containing 50 mM Tris.HCl, pH 7.5 and
10 mM MgCl2 (standard conditions) as described earlier (Santoro &
Joyce, 1997) for 2 h at 37 uC. The cleaved products were resolved by
electrophoresis and cleavage efficiency was determined as described
earlier (Goila & Banerjea, 2001).
Transfections and reporter assay. Monolayers (60–70% conflu-
ent) of Huh7 cells in 35 mm dishes were co-transfected with HCV
monocistronic plasmid pCDHCV-FLuc or pCDCVB3-FLuc or
pCDFLuc. Dzs and pSV-b-gal plasmid were used for normalizing
transfection efficiency using Lipofectamine 2000 (Invitrogen).
Twenty-four hours post-transfection the cells were harvested using
passive lysis buffer (Promega) and FLuc activity was analysed using
a luciferase assay system (Promega) in a TD 20/20 luminometer
(Turner Designs).
Semiquantitative RT-PCR. HCV full-length and subgenomic
replicon-bearing cells were transfected with 0.4 and 0.8 mM Dzs
and, 24 h post-transfection, total cellular RNAs were extracted
using TRI-reagent (Sigma-Aldrich). Semiquantitative RT-PCR was
performed for the HCV-IRES positive strand and actin as described
earlier (Dhar et al., 2007). In brief, 5 mg total RNA was reverse
transcribed with the HCV 59UTR and actin primers by annealing at
65 uC and extending at 42 uC for 50 min. After cDNA was
synthesized, PCR reaction was performed using both 59 and 39
primers specific for HCV 59UTR to amplify and quantify HCV
RNA. The PCR products were run in 1% agarose gel and
densitometric analysis was done using MultiGauge software
(Fujifilm) and the values were expressed as ratio of HCV IRES
to actin.
Northern blot analysis. Total cellular RNA (20 mg) was isolated
from Huh7 cells transfected with HCV–FLuc monocistronic con-
structs with or without Dzs and resolved on formaldehyde-agarose gel
(0.8%) under denaturing conditions. RNA were transferred and
cross-linked to a nylon membrane (Sigma-Aldrich) and probed with a
[a-32P]-labelled firefly luciferase antisense probe, followed by
autoradiography. Densitometric analysis was done and the ratio of
HCV-IRES to 18S rRNA was expressed graphically.
RESULTS
Sequence-specific cleavage of HCV IRES RNA by
various DNAzymes
Since the mechanism of HCV IRES-mediated translation is
novel and fundamentally different from cap-dependent
translation of host cell mRNA, we have designed several
Dzs to target the IRES element for selective inhibition of
HCV RNA translation. Furthermore, the sequence-specific
cleavage in this region will consequently block viral RNA
replication and therefore we designed a number of Dzs that
were targeted to the predicted single-stranded loop regions
within the HCV IRES element (Fig. 1, Tables 1 and 2). In
order to evaluate the cleavage efficiency of the Dzs, in vitro
cleavage reaction were performed. Out of five Dz molecules
only three, Dz219, Dz305, and Dz327, have shown
significant cleavage activity in vitro in cell-free conditions
(Fig. 2a and 2b). Interestingly, the three active Dzs were
found to cleave the target RNA in a sequence-specific
manner with varying efficiencies (Fig. 2b, lanes 3, 4 and 5).
Dz219 showed maximum cleavage activity under standard
Fig. 1. Schematic diagram of HCV IRES (adopted from Brown
et al., 1992), showing the Dz targets. The numbers in bold are
specific for genotype 1b and those in italics are conserved for all
major genotypes.
Table 2. Sequence of DNAzymes for HCV IRES based on
conserved regions
DNAzyme Sequence 5§–3§
Dz161 GTACTCAGGCTAGCTACAACGACGGTTCC
Dz165 CGGTGTAGGCTAGCTACAACGATCACCGG
Dz285 CAGTACCAGGCTAGCTACAACGAAAGGCCT
Dz288 GGCAGTAGGCTAGCTACAACGACACAAGG
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in vitro cleavage conditions (Fig. 2b). However, Dz88 and
Dz336 failed to show detectable cleavage activity.
Further, to investigate the inhibitory effect of Dzs that
would target conserved sequences in all six major
genotypes of HCV, several conserved Dz molecules
(including Dz161, Dz165, Dz285 and Dz288) were
synthesized (Table 1 and Fig. 2a). For this purpose, HCV
59UTR sequences of all six genotypes were aligned using
the CLUSTAL W program (data not shown). The designing of
Dzs was based on the secondary structures of RNA for all
the strains, obtained by the mfold program (data not
shown). All four conserved Dzs were first tested for RNA
cleavage activity in vitro as described before. Among those
four Dz molecules, three, Dz161, Dz285 and Dz288, were
found to cleave the target sequence specifically, the last two
being more efficient (Fig. 2c). Dz165 did not show
significant cleavage activity.
Effect of Dz on HCV IRES-mediated translation ex
vivo
In order to evaluate the intracellular cleavage efficiencies of
the Dz molecules, transient co-transfection experiments
were performed using plasmid HCV–FLuc monocistronic
constructs and the Dz molecules in human hepatocellular
carcinoma cells (Huh7). The monocistronic RNA gener-
ated ex vivo from the HCV–FLuc monocistronic plasmid
encodes the HCV IRES element upstream of the firefly
luciferase reporter gene (Pudi et al., 2003). Although three
Dz molecules specific for genotype 1b showed significant
cleavage activity in vitro, only one of them, Dz219, showed
impressive inhibition (81%) of HCV IRES-mediated
translation. However, the mutant-Dz219 with a single
substitution in the catalytic domain of Dz219 failed to
inhibit HCV IRES-mediated translation, suggesting high
specificity of the approach (Fig. 3a). Interestingly, two
other Dzs (305 and 327) showed significant in vitro
cleavage activity, but failed to interfere with the HCV
translation (Fig. 3a). When conserved Dzs were tested for
inhibition of HCV IRES function, Dz285 and Dz288
showed 38 and 35% inhibition, respectively, whereas
Dz161 showed only 30% inhibition (Fig. 3b).
To investigate the cleavage of the HCV–FLuc monocis-
tronic RNA by the Dzs in ex vivo conditions, Northern blot
hybridization was performed. For this purpose, Huh7 cells
were transiently transfected with the monocistronic DNA
constructs and different Dz molecules (Fig. 4a). Total
RNAs were isolated 24 h post-transfection and used for
Northern assay. Dz molecules used in the assay included
Dz219 and Dz285, which showed maximum activity ex
vivo, and Dz305, Dz327 and mutant-Dz219, that did not
exhibit any ex vivo activity. Results showed significant
cleavage activity of Dz219 and Dz285; however, Dz305 and
Dz327 failed to cleave HCV–FLuc RNA ex vivo (Fig. 4a),
which is consistent with our reporter gene (luciferase) assay
(Fig. 2b). The mutant-Dz219 didn’t show any cleavage
activity ex vivo, as expected. For clarity we have quantified
the band intensity corresponding to the HCV–FLuc RNA
and normalized it with that of the loading control band
(18S rRNA). The densitometric analysis of the ratio of
HCV–FLuc monocistronic RNA to the 18S rRNA (Fig. 4b),
clearly demonstrated that cleavage activity of Dz219 as
48% and that of Dz285 as 25%, respectively. However,
Dz305, Dz327 or the mutant-Dz219 did not exhibit any
significant cleavage activity. Interestingly, the translation
inhibitory activity corresponding to Dz219 and Dz285 was
found to be slightly higher (Fig. 3) than the RNA cleavage
activity (Northern analysis, Fig. 4), which could be due to a
higher sensitivity of the luciferase assay.
To further investigate the specificity of the Dz activity, the
Dz molecules were tested against other viral IRES as well as
cap-dependent translation. For this purpose the pCDFLuc
DNA construct was transiently transfected with represent-
ative Dz molecules (Dz219, 285, 288 and mutant-Dz219)
and the luciferase reporter gene was assayed 24 h
Fig. 2. In vitro cleavage of HCV IRES RNA by various Dz
molecules. (a) Schematic representations of the Dz cleavage sites
on the HCV IRES: HCV genotype 1b-specific Dzs are indicated in
bold, whereas the Dzs that target the conserved sequences across
the different genotypes are indicated in italics. (b) Equimolar
concentrations (100 pmol) of the labelled HCV IRES RNA and
respective Dz were used and the cleavage products were analysed
on 8% PAGE. (c) In vitro cell-free cleavage products of HCV IRES
by conserved Dzs were analysed on 8% PAGE. The asterisks
show the cleavage products as indicated in (a) and their respective
sizes are shown on the right.
S. Roy and others
1582 Journal of General Virology 89
post-transfection. Results suggest that none of the Dz
molecules inhibited the cap-dependent translation of the
luciferase reporter gene (Fig. 5a).
Similarly, CVB3 FLuc monocistronic DNA (pCDCVB3-
FLuc) was cotransfected with the above set of Dz molecules
and the luciferase assay was performed 24 h post-transfec-
tion. Results suggest no significant change in luciferase
activity in presence of the above Dz molecules (Fig. 5b).
Taken together, the results suggest the target specificity of
the Dz molecules and the high levels of selectivity of this
approach.
Effect of Dzs on the HCV RNA replication
Finally, we have analysed the inhibitory effect of the Dzs in
Huh7.5 cells harbouring HCV1b replicon (Fig. 6a) (Blight et
al., 2002). Increasing concentration (0.4 and 0.8 mM) of Dz
219 was transiently transfected into replicon-containing cell
line using Lipofectamine 2000 (Invitrogen). After 24 h, total
RNA was isolated and the HCV positive-strand RNA
corresponding to the 59UTR was detected by semiquanti-
tative RT-PCR. Results suggest approximately 70% inhibi-
tion of the HCV1b genotype replicon RNA synthesis when
0.8 mM Dz219 was used. However, the same concentration
of Dz219 failed to inhibit the HCV-RNA synthesis in Huh7
cells harbouring HCV2a genotype replicon (Lohmann et al.,
1999) (Fig. 6b and 6c). Upon inspection we found that the
Dz219 target sequence was designed on the basis of HCV 1b
sequences, which is not fully conserved in HCV2a sequence.
The result also proved that bio-efficacy of Dz219 was
sequence-specific. Furthermore, when the conserved Dzs
(0.4 mM) were transfected into cells containing HCV
replicon 1b (Fig. 6d), significant inhibition of RNA synthesis
was observed with Dz285 and Dz288 (30 and 50%,
respectively). However, the inhibitory effect was relatively
more pronounced (60% for Dz285 and 70% for Dz288) on
HCV replicon 2a cell line.
DISCUSSION
A couple of studies have demonstrated previously the use
of DNAzyme molecules to cleave HCV RNA ex vivo
(Trepanier et al., 2006), but this study constitutes the first
report on the effect of Dzs on HCV replication in cell lines
harbouring HCV subgenomic or full-length replicons.
Fig. 3. Inhibition of HCV IRES-mediated translation by the Dz
molecules. (a) Approximately 1 mg HCV firefly luciferase mono-
cistronic DNA construct (HCV–FLuc) was transiently cotrans-
fected in Huh7 cells in the absence and presence of 0.4 mM
genotype 1b-specific Dz molecules. Cells were harvested and
luciferase activity measured 24 h post-transfection. The transfec-
tion efficiency was normalized with b-gal activity and the normal-
ized luciferase activity was plotted, taking the control as 100%. (b)
Similarly, 1 mg monocistronic DNA construct (HCV–FLuc ) was
transiently cotransfected in Huh7 cells in the absence and
presence of 0.4 mM conserved Dz molecules. Luciferase activities
were measured 24 h post-transfection. The results represent the
average of three independent experiments done in duplicate.
Fig. 4. Cleavage of HCV RNA ex vivo in Huh7 cells by the Dz
molecules. (a) Northern blot hybridization of the HCV RNA isolated
from Huh7 cells, co-transfected with HCV–FLuc DNA and Dzs
(0.4 mM). Total RNA was isolated using TRIzol reagent 24 h post-
transfection, electrophoresed on formaldehyde agarose gel
(0.8%), blotted on a nylon membrane and hybridized with a32P-
labelled FLuc antisense probe followed by autoradiography. The
numbers below the panels represent the band intensities relative to
control. (b) Graphical representation of the ratio of the densito-
metric values obtained from the respective band intensities
corresponding to HCV-RNA and 18S rRNA.
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Although we have designed several Dzs targeting different
regions of HCV IRES and tested their activities in vitro as
well as ex vivo in cell lines harbouring HCV replicon, only a
couple of them were found to be more effective in the in
vitro and ex vivo assays. Interestingly, when all the Dzs used
in the study were mapped to the target sequences/
structures within HCV IRES (Fig. 1), it appears that the
Dz285 and Dz288, targeting HCV SLIIId loop, and Dz219,
targeting SL IIIb, achieved maximum inhibition, perhaps
due to the importance of the target site in ribosome
assembly during internal initiation of translation. This
could be also due to the fact that all target sites are not
available for efficient cleavage by a single kind of catalytic
nucleic acid molecule, most probably because the second-
ary and tertiary structures in the target RNA prevent
optimal base pairing. Base pairing and cleavage activity also
depend on the arm length of the RNA-binding site of the
Dzs. Enzymes with longer arms sometimes showed higher
cleavage activity compared with enzymes with shorter arms
(Oketani et al., 1999). Modifications in the 59 and 39
termini of these molecules help in preventing nuclease
degradation without affecting its catalytic activity (Oketani
et al., 1999). Interestingly, it has been demonstrated earlier
that the efficiency of some Dz molecules can be enhanced
by using them in combination with some oligodeoxynu-
cleotides (ODNs) which would hybridize the target RNA
near the Dz cleavage site to facilitate the cleavage reaction
(Sood et al., 2007). Thus, it would be interesting to explore
whether the apparently inactive/inefficient Dz molecules in
our study could also be used in combination with ODNs to
potentiate catalytic efficiency for the RNA cleavage.
It appears that, if required, Dz molecules can be used at
higher concentration to achieve maximum inhibition of
viral protein synthesis with minimum effect on host cell
RNA translation (data not shown). It is also possible that
the effective concentration required to achieve 50%
inhibition of viral RNAs could be lowered to a large extent
by using a cocktail of Dz molecules in the line of
combination therapy.
Dz molecules have been shown to be a more stable antiviral
agent compared with Rz or siRNA (Santoro & Joyce, 1997).
Unlike siRNA or shRNAs, Dz molecules are not expected
to activate double-stranded RNA-activated protein kinase
Fig. 6. Effect of Dz molecules ex vivo in replicon cell line. (a)
Schematic representation of the HCV replicon genotype 1a and
1b. (b and c) Increasing concentrations (0.4 and 0.8 mM) of Dz219
were transfected either in Huh7.5 cells harbouring replicon 1b
genotype (b) or Huh7 cells harbouring replicon 2a genotype (c).
RNA was isolated using TRIzol reagent 24 h post-transfection, and
semiquantitative RT-PCR was performed using HCV-59UTR-
specific primers or the actin primers. The products were analysed
on 1% agarose gel. (d and e) Similarly, the effects of Dz285 and
Dz288 (0.4 mM) were analysed with HCV replicon 1b genotype (d)
and HCV replicon 2a genotype (e).
Fig. 5. Effect of Dz molecules on cap-dependent translation and
CVB3 IRES-mediated translation. (a) Dz219, Dz285, Dz288 or
mDz219 (0.4 mM) were co-transfected with 1 mg pCDFLuc DNA
construct and b-gal DNA construct in Huh7 cells. Luciferase assay
was performed 24 h post-transfection. The transfection efficiency
was normalized with b-gal activity and the normalized luciferase
activity was plotted taking the control as 100%. (b) Similarly, 1 mg
CVB3FLuc DNA construct was cotransfected with the above Dzs
and b-gal construct and the normalized luciferase values were
plotted taking the control as 100%. The results shown represent
the average of three independent experiments done in duplicate.
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(PKR) and result in attenuation of host cell RNA
translation due to phosphorylation of eIF2 by PKR (Gil
& Esteban, 2000). It is also possible to make more stable
derivative of the Dzs molecules such as morpholino- or
phosphorothio- derivatives etc. Remarkable stability was
also achieved by modifying (inverting) the first and last
nucleotide residues, especially at the 39-end of the Dz,
which will have serum stability enhanced tenfold (Sun
et al., 1999). In this connection, it has been shown also that
efficient uptake of macrophage tropic-anti-HIV-1 Dz by
human macrophages in the complete absence of charged
lipid molecules can be enhanced by attaching ten G
residues at the 39-end of a 10–23 catalytic motif-containing
Dz. G residues form G quartet-like structures that are
recognized by the scavenger receptor present on macro-
phages (Unwalla & Banerjea, 2001).
Taken together, these results provide proof of the concept
that the HCV IRES could be an effective and selective target
using conserved DNA-enzyme molecules to develop novel
antiviral therapeutics against hepatitis C virus infection. It
would be interesting to couple this with organ-specific
delivery approaches. Liver-specific delivery of Dz molecules
using Sendai virus virosome- (Ramani et al., 1997) or
lentivirus- (Kusunoki et al., 2003) based vectors would be
ideal for developing Dz-based antiviral therapeutics against
hepatitis C virus infection.
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